May 29 Preclinical Quick Takes: Vor debuts lead stem cell program; plus an inverse Alzheimer's-cancer target, and statins for cognitive defects

Vor Biopharma unveils lead candidate comprising CD33-deficient stem cells
Vor Biopharma Inc. co-founder Siddhartha Mukherjee at Columbia University showed transplantation of hematopoietic stem cells with genetic ablation of CD33

Read the full 280 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers